DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Household
Published
24 Sep 24
Updated
07 Aug 26
Views
356
Not Invested
HerbalifeHLF
HLF logo
Fair Value
US$17
Share price07 Aug
US$11.9329.8% undervalued intrinsic discount
Loading
1Y29.53%
7D-4.02%

Global Regulatory Scrutiny Will Undermine MLM And Supplement Models

AN
AnalystConsensusTarget
AnalystConsensusTarget

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
24 Sep 24
Updated
07 Aug 26
Views
356
Not Invested
Fair ValueUS$17
Share priceUS$11.93
29.8% undervalued intrinsic discount
Narrative
Updates10

Last Update 07 Aug 26

Fair value Decreased 7.27%

HLF: 2026 Guidance Execution And Margin Expansion Will Support Share Recovery

Analysts have trimmed their price target on Herbalife to $17 from $21, reflecting updated views on fair value, discount rate, revenue growth, profit margins and future P/E assumptions.

What’s in the News for Herbalife

  • Herbalife raised its full year 2026 net sales guidance to a range of 2.5% to 5.5% year over year, compared with its previous range of 1.5% to 5.5% year over year. Source: company guidance update.
  • The company issued new guidance for the third quarter of 2026, targeting net sales growth of 0.5% to 4.5% year over year. Source: company guidance update.
  • Herbalife announced the planned retirement of long serving Chief Financial Officer John DeSimone, effective December 31, 2026, with Scott Schaefer, currently Senior Vice President of Finance and Transformation, set to become CFO from January 1, 2027. Source: company executive announcement.
  • Herbalife expanded its global Fuel Like Ronaldo campaign with detailed post match recovery guidance built around the 4 R framework (replenish, repair, reinforce and rehydrate), plus an emphasis on rest as a fifth pillar. Source: company product and marketing announcement.

Valuation Changes

  • Fair value has moved lower, with the estimate revised from $18.33 to $17.00.
  • The discount rate has shifted slightly lower, moving from 10.52% to 10.45%.
  • The revenue growth assumption has been reduced, moving from 2.87% to 2.60%.
  • The net profit margin has been revised higher, rising from 5.68% to 9.01%.
  • The future P/E has been cut meaningfully, moving from 8.19x to 4.98x.
Read more
5 viewsusers have viewed this narrative update

Key Takeaways

  • Rising regulatory scrutiny and shifting consumer preferences threaten future growth, profitability, and increase compliance costs for the company's traditional business model.
  • Flat volumes, maturing markets, and negative MLM perceptions undermine growth initiatives, leaving revenue and margins vulnerable to macroeconomic volatility.
  • Emphasis on innovation, technology, and distributor engagement is boosting operational efficiency, customer retention, and financial flexibility amid rising demand for personalized wellness solutions.

Catalysts

About Herbalife
    Provides health and wellness products in North America, Mexico, South and Central America, Europe, the Middle East, Africa, China, and the Asia Pacific.
What are the underlying business or industry changes driving this perspective?
  • Investors may be underestimating the risk of increasing global regulatory scrutiny on multi-level marketing (MLM) models and nutritional supplement claims, which could raise compliance costs, limit distributor activity in key regions, and constrain Herbalife's long-term revenue and earnings growth.
  • Secular consumer trends toward whole, natural foods and growing skepticism of processed supplements may impair demand for Herbalife's core products, potentially leading to slower revenue growth and higher customer acquisition costs as consumer preferences evolve.
  • The company continues to experience flat to declining volumes in several regions, with only modest improvements in constant currency net sales, indicating that the addressable market for Herbalife's traditional model may be reaching maturity and that top-line revenue growth could remain pressured.
  • Ongoing reliance on network recruiting and regional distributor growth increases vulnerability to macroeconomic downturns and currency headwinds in emerging markets, which may result in heightened volatility in both revenue and net margins.
  • Challenges in breaking away from negative public perceptions around the MLM structure and hesitancy in successfully transforming into a technology-focused, personalized wellness platform could limit the effectiveness of current growth initiatives-constraining long-term sales expansion and profit margin improvement.
Herbalife Earnings and Revenue Growth

Herbalife Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Herbalife's revenue will grow by 2.6% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 3.2% today to 9.0% in 3 years time.
  • Analysts expect earnings to reach $506.4 million (and earnings per share of $3.43) by about August 2029, up from $164.2 million today.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 5.0x on those 2029 earnings, down from 7.9x today. This future PE is lower than the current PE for the US Personal Products industry at 15.5x.
  • Analysts expect the number of shares outstanding to grow by 1.65% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 10.45%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Herbalife's transformation into a next-generation, data-driven wellness company-including its investments in product innovation (e.g., healthy lifespan supplements, MultiBurn) and personalized technology platforms (Pro2col, Link Biosciences)-positions it to capitalize on the major secular trend of rising consumer demand for personalized and preventative health solutions, potentially leading to increased revenue and higher customer retention.
  • The company is seeing early signs of accelerating momentum in key markets, particularly North America, with July marking the first month of year-over-year volume growth in the region since 2021, which could signal a reversal of past declines and bolster top-line growth.
  • Expansion of digital engagement, AI-driven marketing, subscription-based offerings, and enhanced distributor tools is increasing operational efficiencies and recurring revenues, supporting improved net margins and cash flow generation over the longer term.
  • Strong engagement and stability within the distributor network-evidenced by flat global new distributor growth, high engagement at major events, and enthusiastic adoption of new technology-demonstrate resilience and adaptability of the business model, reducing downside risk to earnings.
  • Ongoing debt reduction and disciplined capital management, including paying down $55 million of debt this quarter and maintaining leverage at 3x, leaves Herbalife in a stronger financial position, providing flexibility for future investment and potentially supporting sustained earnings and shareholder value.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of $17.0 for Herbalife based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $25.0, and the most bearish reporting a price target of just $9.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $5.6 billion, earnings will come to $506.4 million, and it would be trading on a PE ratio of 5.0x, assuming you use a discount rate of 10.4%.
  • Given the current share price of $12.35, the analyst price target of $17.0 is 27.4% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Herbalife?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Comments

0 comments

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

HLF logo
Herbalife
52.3% undervalued intrinsic discount

Digital Platforms And Personalized Nutrition Will Expand Wellness Despite Headwinds

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 3 Jun
Read Narrative
HLF logo
Herbalife
32.6% overvalued intrinsic discount

Intensifying Regulatory Pressures And Distributor Disruptions Will Imperil Future Prospects

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 23 Mar
Read Narrative

Fair Value vs Share Price

US$17
vs US$11.9329.8% undervalued intrinsic discount
PastFuture06b2015201820212024202620272029Revenue US$5.6bEarnings US$506.4m
2.6%
Revenue growth
9%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Herbalife

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Undervalued with slight risk.

Market capUS$1.3b
PB-2.6x
Estimated Growth2.6%
Dividend Yield0%
Full analysis

CEO & management

Stephan Gratziani
CEO
2.4yrs
CEO Tenure

Provides health and wellness products in North America, Mexico, South and Central America, Europe, the Middle East, Africa, China, and the Asia Pacific.

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide